MedTrace Logo

NOW Thai HAART Study

NCT00367731 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2006-08-23

No results posted yet for this study

Summary

After Initiation of HAART in peoples who living with HIV/AIDS in Thailand by the year 2000, rapidly expanded HAART access of national project has been promoted in 2004. Free ARVs (For CD4\<200cell/cu.mm. or in symptomatic HIV with CD4\<250 cell/cu.mm. )and CD4 monitoring has been available. The first-line regimen is d4T+3TC+NVP in mainly the first time (Naive) patients. CD4 response ), rate of opportunistic infection, and neurological outcomes were measured. Rate of ARV change, adverse events,treatment failure, TB co-infection rate, percent changing to EFV-based regimen or PI-based regimen were recorded.

Any Adverse Events including, Sever rash, Severe Hepatitis, Lipid abnormalities, Severe Anemia and Other, common AEs will be analysed.

Conditions

  • HIV
  • AIDS
  • Neurological Complications

Interventions

DRUG

Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI)

Sponsors & Collaborators

  • Rajavithi Biomolecular Research Center

    collaborator OTHER

  • Department of Medical Services Ministry of Public Health of Thailand

    lead OTHER_GOV

Principal Investigators

  • Subsai Kongsaengdao, M.D. · Department of Medical Services Ministry of Public Health of Thailand

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Completion
2006-09-30

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00367731 on ClinicalTrials.gov